Compare CTSO & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | HBIO |
|---|---|---|
| Founded | 1997 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 26.5M |
| IPO Year | 2008 | 2000 |
| Metric | CTSO | HBIO |
|---|---|---|
| Price | $0.37 | $7.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.38 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 68.3K | 18.1K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $22,503,908.00 | ★ $116,176,000.00 |
| Revenue This Year | $10.34 | $4.77 |
| Revenue Next Year | $22.41 | $8.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.53 | N/A |
| 52 Week Low | $0.30 | $0.38 |
| 52 Week High | $1.04 | $7.63 |
| Indicator | CTSO | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 70.10 |
| Support Level | $0.36 | $5.91 |
| Resistance Level | $0.40 | $7.50 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | -0.00 | 0.12 |
| Stochastic Oscillator | 58.70 | 86.73 |
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.